



DAFTAR PUSTAKA

- Abulafia, J., Vignale, R.A. 1999. Leprosy: Pathogenesis updated. *Int J Dermatol*, 38: 321-334.
- Adhe, V., Dongre, A., Khopkar, U. 2012. A retrospective analysis of histopathology of 64 cases of lepra reactions. *Indian J Dermatol*, 57:114-117.
- Agarwal, P., Rashighi, M., Essien, K.I., Richmond, J.M., Pazoki-Toroudi, H., Hunter, C.A., Harris, J.E. 2015. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. *J Invest Dermatol*, 135:1080-1088.
- Ahmed, A.A., Nordlind, K., Schultzberg, M., Liden, S. 1994. Interleukin-1 alpha and beta-, interleukin-6-and tumour necrosis factor-alpha-like immunoreactivities in chronic granulomatous skin conditions. *Acta Derm Venereol*, 74(6): 435-440.
- Aires, N., Refkalefsky, L., Villela, M., Sakai, V., Trindade, M. 2009. Sweet's syndrome type leprosy reaction. *J Eur Acad Dermatol Venereol*, 23:467-469.
- Akira, S., Taga, T., Kishimoto, T. 1993. Interleukin-6 in biology and medicine. *Adv Immunol*, 54: 1-78.
- Amsen, D., de Visser, K.E., Town, T. 2009. Approaches to determine expression of inflammatory cytokines. *Methods Mol Biol*, 511: 107-142.
- Antunes, D.E., Ferreira, G.P., Nicchio, M.V.C., Araujo, S., Da Cunha, A.C.R., Gomes, R.R., Da Costa, A.V., Goulart, I.M.B. 2016. Number of leprosy reactions during treatment: Clinical correlations and laboratory diagnosis. *Rev Soc Bras Med Trop*, 49:741-745.
- Arora, M., Katoch, K., Natrajan, M., Kamal, R., Yadav, V.S. 2008. Changing profile of disease in leprosy patients diagnosed in a tertiary care centre during years 1995-2000. *Indian J Lepr*, 80(3): 257-265.
- Ataie-Kachoe, P., Pourgholami, M., Richardson, D., Morris, D.L. 2014. Gene of the month: Interleukin 6 (IL-6). *J Clin Pathol*, 0:1-6.
- Atkinson, S., Khanolkar-Young, S., Marlowe, S., Jain, S., Reddy, R., Suneetha, S., Lockwood, D. 2004. Detection of IL-13, IL-10, and IL-6 in the leprosy skin lesions of patients during prednisolone treatment for type 1 reactions (T1R). *Int J Lepr Other Mycobact Dis*, 72: 27-34.
- Balagon, M.V.F., Gelber, R.H., Abalos, R.M., Cellona, R.V. 2010. Reactions following completion of 1 and 2 year multidrug therapy (MDT). *Am J Trop Med Hyg*, 83. 637-644.
- Barua, J.K., Anurag, D., Barik, G., Perna, Ghoshal, L., Shukla, D.K., Banerjee, G. 2016. A clinico-epidemiological study of leprosy in an urban leprosy centre of West Bengal. *IOSR JDMS* 15: 12-15.
- Beharka, A., Meydani, M., Wu, D., Leka, L., Meydani, A., Meydani, S. 2001. Interleukin-6 production does not increase with age. *J Gerontol A Biol Sci Med Sci*, 56: B81-B88.
- Belgaumkar, V.A., Gokhale, N.R., Mahajan, P.M., Bharadwaj, R., Pandit, D.P., Deshpande, S. 2007. Circulating cytokine profiles in leprosy patients. *Lepr Rev*, 78: 223-230.
- Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T., Oukka, M., Weiner, H.,



- Kuchroo, V. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature*, 441: 235–238.
- Bhat, R.M., Prakash, C. 2012. Leprosy: An overview of pathophysiology. *Interdiscip Perfect Infect Dis*, 2012: 1–7.
- Bi, Y., Liu, G., Yang, R. 2007. Th17 cell induction and immune regulatory effects. *J Cell Physiol*, 211: 273–278.
- Bienvenu, J.A., Monneret, G., Gutowski, M.C., Fabien, N. 1998. Cytokine assays in human sera and tissues. *Toxicology*, 129: 55-61.
- Bragoni, A., Gambella, A., Pigozzi, S., Grigolini, M., Fiocca, R., Mastracci, L., Grillo, F. 2017. Quality control in diagnostic immunohistochemistry: Integrated slide positive controls. *Histochem Cell Biol*, 148: 569-573.
- Brito M.F., Ximenes, R., Gallo, M., Bühner-Sékula, S. 2008. Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy. *Rev Soc Bras Med Trop*, 41: 67–72.
- Bryceson, A., Pfaltzgraff, R. 1990. *Leprosy*. 3rd ed., Churchill Livingstone, New York.
- Burdick, A., Ramirez, C. 2001. The role of mycophenolate mofetil in the treatment of leprosy reactions. *Int J Lepr Other Mycobact Dis*, 73(2): 127–128.
- Camp, R.L., Charette, L.A., Rimm, D.L. 2000. Validation of tissue microarray technology in breast carcinoma. *Lab Invest*, 80(12): 1943-1949.
- Castells-Rodellas, A., Castell, J.V., Ramirez-Bosca, A., Nicolas, J.F., Valcuende-Cavero, F., Thivolet, J. 1992. Interleukin-6 in normal skin and psoriasis. *Acta Derm Venereol*, 72(3): 165-168.
- Chaitanya, V.S., Lavania, M., Nigam, A., Turankar, R.P., Singh, I., Horo, I., Sengupta, U., Jadhav, R.S. 2013. Cortisol and proinflammatory cytokine profiles in type 1 (reversal) reactions of leprosy. *Immunol Lett*, 156(1-2): 159-167.
- Chapman, B., Khan, A., Harper, M., Stockman, D., Fiscella, K., Walton, J., Duberstein, P., Talbot, N., Lyness, J., Moynihan, J. 2009. Gender, race/ethnicity, personality, and interleukin-6 in urban primary care patients. *Brain, Behav, Immun*, 23: 636–642.
- Chastain, L.L., Calhoun, K., Schartz, T., Gallucci, R.M. 2016. IL-6 influences the balance between M1 and M2 macrophage mouse model of irritant contact dermatitis. *J Immunol*, 196: 17443-17454.
- Chowdhry, S., Shukla, A., Paschal, D., Dhali, T., Jaiswal, P. 2016. Treatment of severe refractory erythema nodosum leprosum with tumor necrosis factor inhibitor Etanercept. *Int J Mycobacteriol*, 5(2): 1–3.
- Cortela, D.C.B., De Souza Junior, A.L., Virmond, M.C.L., Ignotti, E. 2015. Inflammatory mediators of leprosy reactional episodes and dental infections: A systematic review. *Mediators Inflamm*, 2015: 1-15.
- Costa, C.F., Medeiros, N.I., Chaves, A.T., Lyon, S., Coelho-dos-Reis, J.G.A., Ribeiro-Junior, A.F., Correa-Oliveira, R., Rocha, M.O.C., Gomes, J.A.S. 2017. Cytokines as biomarkers to monitoring the impact of multidrug therapy in immune response of leprosy patients. *Cytokine*, 97: 42-48.
- Cuevas, J., Rodríguez-Peralto, J., Carrillo, R., Contreras, F. 2007. Erythema



- nodosum leprosum: Reactional leprosy. *Semin Cutan Med Surg*, 26:126-130.
- Da Costa Nery, J.A., Filho, F.B., Quintanilha, J., Machado, A.M., Oliveira, S.S.C., Sales, A.M. 2013. Understanding the type 1 reactional state for early diagnosis and treatment: A way to avoid disability in leprosy. *An Bras Dermatol*, 88: 787-792.
- Dahlan, S. 2014. Statistik untuk kedokteran dan kesehatan: Deskriptif, bivariat, dan multivariat dilengkapi aplikasi menggunakan SPSS. Epidemiologi Indonesia, Jakarta.
- Degang, Y., Akama, T., Hara, T., Tanigawa, K., Ishido, Y., Gidoh, M., Makino, M., Ishii, N., Suzuki, K. 2012. Clofazimine modulates the expression of lipid metabolism protein in *Mycobacterium leprae*-infected macrophages. *PLoS Negl Trop Dis*, 6: 1-8.
- De Sousa, J.R., Neto, F.D.L., Sotto, M.N., Quaresma, J.A.S. 2018. Immunohistochemical characterization of the M4 macrophage population in leprosy skin lesions. *BMC Infect Dis*, 18(1): 576.
- De Sousa, J.R., Sotto, M.N., Quaresma, J.A.S. 2017. Leprosy as a complex infection: breakdown of the th1 and th2 immune paradigm in the immunopathogenesis of the disease. *Front Immunol*, 8:1-8.
- Dhillon, K. S., Sharma, D., Singh, T., Tandon, N., Sarin, G., Khan, A., Yadav, S., Srivastava, S. 2015. Erythema necroticans: A rare reaction pattern in leprosy. *I J Medicine*, 2(2): 185–187.
- Diehl, S., Rincon, M. 2002. The two faces of IL-6 on Th1/Th2 differentiation. *Mol Immunol*, 39: 531-536.
- Dinas Kesehatan DIY. 2017. *Profil kesehatan provinsi DI Yogyakarta tahun 2017*. Kementerian Kesehatan RI, Jakarta.
- Duraiyan, J., Govindarajan, R., Kaliyappan, K., Palanisamy, M. 2012. Applications of immunohistochemistry. *J Pharm Bioallied Sci*, S307-S309.
- Duthie, M., Raychaudhuri, R., Tutterrow, Y., Misquith, A., Bowman, J., Casey, A., Balagon, M., Maghanoy, A., Beltran-Alzate, J., Romero-Alzate, M., Cardona-Castro, N., Reed, S.G. 2014. A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugate. *Diagn Microbiol Infect Dis*, 79: 233–239.
- Dwork, A.J., Liu, D., Kaufman, M.A., Prohovnik, I. 1998. Archival, formalin-fixed tissue: its use in the study of Alzheimer's type changes. *Clin neuropathol*, 17(1): 45-49.
- Efrizal, E., Lazuardi, L., Soebono, H. 2016. Faktor risiko dan pola distribusi kusta di Yogyakarta. *BKM*, 32: 347–352.
- Eichelmann, K., González, S.E., Salas-Alanis, J.C., Ocampo-Candiani, J. 2013. Leprosy. An update: Definition, pathogenesis, classification, diagnosis, and treatment. *Actas Dermo-Sifiliográficas*, 104(7): 554–563.
- Faber, W., Jensema, A., Goldschmidt, W. 2006. Treatment of recurrent erythema nodosum leprosum with Infliximab. *N Engl J Med*, 7: 738–739.
- Fink, S., De la Barrera, S., Minnucci, F., Valdez, R., Balina, L.M., Sasiain, M.C. 1993. IFN- γ , IL-6 and IL-4 modulate M. leprae- or PPD-specific cytotoxic T cells in leprosy patients. *Scand J Immunol*, 38(6): 551-558.
- Flattersa, S., Foxb, A., Dickenson, A. 2004. Nerve injury alters the effects of



- interleukin-6 on nociceptive transmission in peripheral afferents. *Eur J Pharmac*, 484: 183–191.
- Gabay, C. 2006. Interleukin-6 and chronic inflammation. *Arthritis Res Ther*, 8:1-6.
- Gabay, C., Smith, M.F., Eidlen, D., Arend, W.P. 1997. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. *J Clin Invest*, 99(120): 2930-2940.
- Goodman, W.A., Levine, A.D., Massari, J.V., Sugiyama, H., McCormick, T.S., Cooper, K.D. 2009. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. *J Immunol*, 183(5): 3170-3176.
- Gordon, M.Y. 1991. Hemopoietic growth factors and receptors: bound and free. *Cancer cells*, 3: 127-133.
- Gorniak, B.G., Puszczewicz, M. Fatigue and interleukin-6 – A multi-faceted relationship. *Reumatologia*, 53: 207-212.
- Grillo, F., Bruzzone, M., Pigozzi, S., Prosapio, S., Migliora, P., Fiocca, R., Mastracci, L. Immunohistochemistry on old archival paraffin blocks: Is there expiry date? *J Clin Pathol*, 70: 988-993.
- Gupta, A., Sharma, V.K., Vohra, H., Ganguly, N.K. 1999. Spontaneous apoptosis in peripheral blood mononuclear cells of leprosy patients: Role of cytokines. *FEMS Immunol Med Microbiol*, 24: 49-55.
- Haroon, E., Raison, C.L., Miller, A.H. 2012. Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. *Neuropsychopharmacology*, 37: 137-162.
- Hayki, A.N., Al-Mahmoud, B. 2011. Erythema necroticans: A presenting manifestation of silent leprosy. *J Dermatol Dermatol Surg*, 15: 63-66.
- Heng, Y., Chiam, Y., Giam, Y., Chong, W. 2011. Lepromatous leprosy in erythema nodosum leprosum reaction mimicking Sweet's syndrome. *Int J Dermatol*, 50: 1124–1125.
- Hewitt, S.M., Baskin, D.G., Frevert, C.W., Stahl, W.L., Rosa-Molinar, E. 2014. Controls for immunohistochemistry: the Histochemical Society's standards of practice for validation of immunohistochemical assays. *J Histochem Cytochem*, 62(10): 693-697.
- Hofman, F. 2002. Immunohistochemistry. *Curr Protoc Immunol*, 21: 1–23.
- Hungria, E.M., Sekula, S.B., De Oliveira, R.M., Aderaldo, L.C., Pontes, A.A., Cruz, R., Goncalves, H.S., Penna, M.L.F., Penna, G.O., Stefani, M.M.A. 2017. Leprosy reactions: The predictive value of *Mycobacterium leprae*-specific serology evaluated in a Brazilian cohort of leprosy patients (UMDT/CT-BR). *PLoS Negl Trop Dis*, 11: 1-17.
- Iyer, A., Hatta, M., Usman, R., Luiten, S., Oskam, L., Faber, W., Geluk, A., Das, P. 2007. Serum levels of interferon- γ , tumour necrosis factor- α , soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. *Clin Exp Immunol*, 150: 210-216.
- Jablonowska, M., Milnerowicz, H., Rabczynski, J., Milnerowicz, S., Nabzdyk, S., Patrzalek, D., Milnerowicz, A. 2008. Immunohistochemical localization of interleukin-6 in human pancreatitis. *Appl Immunohistochem Mol Morphol*, 16(1): 40-43.
- Jensen, E.C. 2013. Quantitative analysis of histological staining and fluorescence



- using ImageJ. *Anat Rec*, 296(3): 378-381.
- Jones, S.A., Scheller, J., Rose-John, S. 2011. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. *Journal Clin Invest*, 121(9): 3375-3383.
- Jones, S.A., Takeuchi, T., Aletaha, D., Smolen, J., Choy, E.H., McInnes, I. 2018. Interleukin 6: The biology behind the therapy. *Considerations Med*, 2: 2-6.
- Kahawita, I.P., Lockwood, D.N.J. 2008. Towards understanding the pathology of erythema nodosum leprosum. *Trans R Soc Trop Med Hyg*, 102: 329-337.
- Kahawita, I., Walker I.S., Lockwood, D.N.J. 2008. Leprosy type 1 reactions and erythema nodosum leprosum. *An. Bras. Dermatol*, 83: 75-82.
- Kang, B., Chung, E., Yun, Y., Lee, M., Lee, Y., Lee, K., Min, K., Kim, Y. 2001. Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. *Biol Pharm Bull*, 24: 701-703.
- Kar, H, Gupta, R. 2015. Treatment of leprosy. *Clinics in Dermatology*, 33: 55-65.
- Kementerian Kesehatan RI. 2012. *Pedoman Nasional Program Pengendalian Penyakit Kusta*. Kementerian Kesehatan RI, Jakarta.
- Kementerian Kesehatan RI. 2018. *Infodatin Kusta 2018: Hapuskan stigma dan diskriminasi terhadap kusta*. Kementerian Kesehatan RI, Jakarta.
- Kishimoto, T. 1989. The biology of interleukin-6. *Blood*, 74(1): 1-10.
- Kishimoto, T. 2006. Interleukin-6: Discovery of a pleiotropic cytokine. *Arthritis Res Ther*, 8: S2.
- Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., Köhler, G. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. *Nature*, 368: 339-342.
- Korn, T., Bettelli, E., Oukka, M., Kuchroo, V. 2009. IL-17 and Th17 cells. *Annu Rev Immunol*, 27: 485-517.
- Kumar, B., Dogra, S., Kaur, I. 2004. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. *Int J Lepr Other Mycobact Dis*, 72: 125-133.
- Kumar, H., Kawai, T., Akira, S. 2011. Pathogen recognition by the innate immune system. *Int Rev Immunol*, 30: 16-34.
- Lastória, J., Aparecida, M., De Abreu, M. 2014a. Leprosy: A review of laboratory and therapeutic aspects - Part 2. *An Bras Dermatol*, 89: 389-401.
- Lastória, J., De Abreu, M. 2014b. Leprosy: Review of the epidemiological, clinical, and etiopathogenic aspects - Part 1. *An Bras Dermatol*, 89: 205-218.
- Leal, A.M.O., Magalhães, P.K.R., Souza, C.S., Foss, N.T. 2006. Pituitary-gonadal hormones and interleukin patterns in leprosy. *Trop Med Int Health*, 11(9): 1416-1421.
- Lee, D., Rea, T., Modlin, R.L. 2012. Leprosy. In: Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S., Leffell, D., Wolff, K., editor, *Fitzpatrick's Dermatology in General Medicine*. 8th ed., Mc Graw Hill, New York.
- Lin, F. and Chen, Z., 2014. Standardization of diagnostic immunohistochemistry: literature review and geisinger experience. *Arch Pathol Lab Med*, 138(12): 1564-1577.
- Litlekalsoy, J., Vatne, V., Hostmark, J.G., Laerum, O.D. 2007. Immunohistochemical markers in urinary bladder carcinomas from paraffin



- embedded archival tissue after storage for 5–70 years. *BJU Int*, 99(5): 1013-1019.
- Lockwood, D.N.J., Colston, M., Khanolkar-Young, S. 2002. The detection of *Mycobacterium leprae* protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. *Am J Trop Med Hyg*, 66: 409–415.
- Lockwood, D.N.J., Lavanya, S., Sagili, K.D., Chaduvula, M.V., Mohammed, I., Van Brakel, W., Smith, W.C., Nicholls, P., Suneetha, S. 2011. Cytokine and protein markers of leprosy reactions in skin and nerves: Baseline results for the North Indian INFIR. *PLoS Neg Trop Dis*, 5: 1-17.
- Lockwood, D.N.J., Sinha, H.H. 1999. Pregnancy and leprosy: a comprehensive literature review. *Int J Lepr Other Mycobact Dis*, 67(1): 6-12.
- Ma, C., Deenick, E., Batten, M., Tangye, S. 2012. The origins, function, and regulation of T follicular helper cells. *J Exp Med*, 209: 1241–1253.
- Liu, Y.Y., Yu, M.W., Ning, Y., Wang, H. 2018. A study on gender differences in newly detected leprosy cases in Sichuan, China, 2000-2015. *Int J Dermatol*, 57: 1492-1499.
- Magaña, M. 2006. Eritema necrosante o fenómeno de Lucio. Vasculitis? De qué tipo, de qué vasos, qué mecanismo? *Acta Dermatol Dermatopatol*, 6: 5–7.
- Maity, B., Sheff, D., Fisher, R.A. 2013. Immunostaining: Detection of signaling protein location in tissues, cells, and subcellular compartments. *Methods Cell Biol*, 113: 81-105.
- Malathi, M., Thappa, D. 2013. Fixed-duration therapy in leprosy: Limitations and opportunities. *Indian J Dermatol*, 58: 93–100.
- Mathur, M.C., Ghimire, R.B., Shrestha, P., Kedia, S.K. 2011. Clinicohistopathological correlation in leprosy. *Kathmandu Univ Med J*, 9: 248-251.
- Mayboroda, O. A., Van Hooij, A., Derks, R., Eeden, S.J.F. Van Den Dijkman, K., Khadge, S., Thapa, P., Kunwar, C.B., Hagge, D.A., Geluk, A. 2016. Exploratory urinary metabolomics of type 1 leprosy reactions. *Int J Infect Dis*, 45: 46–52.
- Miranda, A., Antunes, S., Nery, J., Sales, A., Pereira, M., Sarno, E. 2012. Erythema multiforme in leprosy. *Mem Inst Oswaldo Cruz*, 107: 34–42.
- Moraes, M.O., Sarno, E.N., Almeida, A.S., Saraiva, B.C., Nery, J.A., Martins, R.C., Sampaio, E.P. 1999. Cytokine mRNA expression in leprosy: A possible role for interferon- γ and interleukin-12 in reactions (RR and ENL). *Scand J Immunol*, 50: 541-549.
- Motta, A.C.F., Pereira, K.J., Tarquinio, D.C., Vieira, M.B., Miyake, K., Foss, N.T. 2012. Leprosy reactions: Coinfections as a possible risk factor. *Clinics (Sao Paulo)*, 67:1145-1148.
- Moubasher, A., Kamel, N., Zedan, H., Raheem, D. 1998. Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy. *Int J Dermatol*, 37:741–746.
- Mudter, J., Neurath, M.F. 2007. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. *Inflamm Bowel Dis*, 13(8): 1016-1023.



- Nada, E.A., Taieb, M., El, B., Fayed, H.C., Ibrahim, H.D., Yasin, Y. 2018. Serum interleukin-6 and interferon- γ in patients with leprosy. *Egypt J Dermatol Venereol*, 28: 80–84.
- Nath, I. 2016. Immunopathogenesis of Leprosy: A model for T cell anergy. *EMJ Dermatol*, 4: 95–101.
- Negera, E., Walker, S.L., Girma, S., Doni, S.N., Tsegaye, D., Lambert, S.M., Idriss, M.H., Tsegay, Y., Dockrell, H.M., Aseffa, A., Lockwood, D.N. 2017. Clinico-pathological features of erythema nodosum leprosum: A case-control study at ALERT hospital, Ethiopia. *PLoS Negl Trop Dis*. 11: 1-13.
- Nigam, P., Kumar, P., Pathak, N., Mittal, S. 2007. Fine needle aspiration cytology in reactional and non-reactional leprosy. *Indian J Dermatol Venereol Leprol*, 73: 247–249.
- Nogueira, P.S.F., Moura, E.R.F., Dias, A.A., Américo, C.F., Aguiar, L.R., Valente, M.M.Q.P. 2015. Characteristics of pregnant and lactating women with leprosy. *Rev Soc Bras Med Trop*, 48: 96-98.
- Ochoa, M.T., Valderrama, L., Ochoa, A., Zea, A., Escobar, C.E., Moreno, L.H., Falabella, R. 1996. Lepromatous and tuberculoid leprosy: clinical presentation and cytokine responses. *Int J Dermatol*, 35(11): 786-790.
- Pandhi, D., Chhabra, N. 2013. New insights in the pathogenesis of type 1 and type 2 lepra reaction. *Indian J Dermatol Venereol Leprol*, 79: 739–749.
- Paquet, P. dan Pierard, G.E. 1996. Interleukin-6 and the skin. *Int Arch Allergy Immunol*, 109: 308-317.
- Pinheiro, R., Salles, J., Sarno, E., Sampaio, E. 2011. Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: An overview. *Future Microbiol*, 6: 217–230.
- Pires, C., Quaresma, J., De Souza Aarão, T., De Souza, J., Macedo, G., Neto, F., Xavier, M. 2017. Expression of interleukin-1 β and interleukin-6 in leprosy reactions in patients with human immunodeficiency virus coinfection. *Acta Tropica*, 172: 213–216.
- Pocaterra, L., Jain, S., Reddy, R., Muzaffarullah, S., Torres, O., Suneetha, S., Lockwood, D.N. 2006. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. *Am J Trop Med Hyg*, 74(5): 868-879.
- Pratamasari, M., Listiawan, M. 2015. Studi retrospektif: Reaksi kusta tipe 1. *BIKKK*, 27: 137–143.
- Radstake, T.R., van Bon, L., Broen, J., Hussiani, A., Hesselstrand, R., Wuttge, D.M., Deng, Y., Simms, R., Lubberts, E., Lafyatis, R. 2009. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGF β and IFN γ distinguishes SSc phenotypes. *PLoS One*, 4(6): 1-9.
- Raffe, S., Thapa, M., Khadge, S., Tamang, K., Hagge, D., Lockwood, D. 2013. Diagnosis and treatment of leprosy reactions in integrated services-The patients' perspective in Nepal. *PLoS Negl Trop Dis*, 7: e2089.
- Ramos, E.S.M., De Castro, M. 2012. Mycobacterial infections. In: Bologna, J., Jorizzo, J., Schaffer, J., editor. *Dermatology*. 3rd ed. Elsevier, New York
- Ramos, E., Oliveira, M., Munhoz da Fontoura, G. 2005. Leprosy: Uncommon presentations. *Clin Dermatol*, 23: 509–514.



- Ramos, J.M., Martínez-Martín, M., Reyes, F., Lemma, D., Belinchón, I., Gutiérrez, F. 2012. Gender differential on characteristics and outcome of leprosy patients admitted to a long-term care rural hospital in South-Eastern Ethiopia. *Int J Equity Health*, 11(1): 56.
- Ranefall, P., Wester, K., Bengtsson, E. 1998. Automatic quantification of immunohistochemically stained cell nuclei using unsupervised image analysis. *Anal Cell Pathol*, 16(1): 29-43.
- Ranque, B., Van Thuc, N., Vu, H.T., Nguyen, T.H., Nguyen, N.B., Pham, X.K., Schurr, E., Abel, L., Alcais, A. 2007. Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. *Clin Infect Dis*, 44(1): 33-40.
- Reibel, F., Cambau, E., Aubry, A. 2015. Update on the epidemiology, diagnosis, and treatment of leprosy. *Medecine et Maladies Infectieuses*, 45(9): 383-393.
- Rincon, M., Anguita, J., Nakamura, T., Fikrig, E., Flavell, R.A. 1997. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4⁺ T cells. *J Exp Med*, 185: 461-470.
- Roche, P.W., Le Master, J., Butlin, C.R. 1997. Risk factors for type 1 reactions in leprosy. *Int J Lepr Other Mycobact Dis*, 65: 450-455.
- Rodrigues, A., De Almeida, A., De Freitas Rodrigues, B., Pinheiro, C., De Mendonca, M., Da Silva, V., Goulart, I. 2000. Occurrence of late lepra reaction in leprosy patients: Subsidies for implementation of a specific care program. *Hansen. Int*, 25: 17-25.
- Rolls, G., Westra, S., Anderson, J. 2019. Immunohistochemistry: An overview + steps to better IHC staining. [online] Available at: <https://www.leicabiosystems.com/pathologyleaders/immunohistochemistry-an-overview-steps-to-better-ihc-staining/>. [Accessed 3 April 2019].
- Rose-John, S., Heinrich, P.C. 1994. Soluble receptors for cytokines and growth factors: generation and biological function. *Biochem J*, 300(Pt 2): 281-290.
- RSUP Dr. Sardjito. 2018. Catatan Medik RSUP Dr. Sardjito Yogyakarta. *Unpublished*.
- Saini, C., Ramesh, V., Nath, I. 2013. CD4⁺ Th17 cells discriminate clinical types and constitute a third subset of non Th1, non Th2 t cells in human leprosy. *PLoS Negl Trop Dis*, 7:1-13.
- Saini, C., Siddiqui, A., Ramesh, V., Nath, I. 2016. Leprosy reactions show increased Th17 cell activity and reduced FOXP3⁺ Tregs with concomitant decrease in TGF- β and increase in IL-6. *PLoS Negl Trop Dis*, 10: 1-21.
- Sakamoto, H., Sakamaki, T., Kanda, T., Hirao, Y., Ohyama, Y., Ogishi, K., Negishi, M., Masuda, H., Sumino, H., Sawada, Y., Ono, Z., Kobayashi, I., Nagai, R. 1997. Immunosuppressive drugs inhibit the production of interleukin-6 and interleukin-8 in cultured cardiac myxoma cells. *Res Commun Mol Pathol Pharmacol*, 97: 60-66.
- Sales-Marques, C., Cardoso, C., Alvarado-Arnez, L., Illaramendi, X., Sales, A., De Andrea Hacker, M., De Mattos Barbosa, M., Da Costa Nery, J., Al, E. 2017. Genetic polymorphisms of the IL6 and NOD2 genes are risk factors for inflammatory reactions in leprosy. *PLoS Negl Trop Dis*, 11: 1-16.
- Sales, A., Illaramendi, X., Walker, S., Lockwood, D., Sarno, E., Da Costa Nery,



- J., Nery, C. 2017. The impact of erythema nodosum leprosum on health related quality of life in Rio de Janeiro. *Lepr Rev*, 88: 499–509.
- Salgado, C., Vilson, F., NR, M., Al, E. 2011. Cellular inflammation in nonarteritic anterior ischemic optic neuropathy and its primate model. *Arch Ophthalmol*, 129: 1583–1592.
- Santos, A., Balassiano, V., Oliveira, M., Pereira, M., Santos, P., Degrave, W. 2001. Detection of *Mycobacterium leprae* DNA by polymerase chain reaction in the blood of individuals, eight years after completion of anti-leprosy therapy. *Mem Inst Oswaldo Cruz*, 96: 1129–1133.
- Sarita, S., Muhammed, K., Najeeba, R., Rajan, G., Anza, K., Binitha, M., Aparna, G. 2013. A study on histological features of lepra reactions in patients attending the Dermatology Department of the Government Medical College, Calicut, Kerala, India. *Lepr Rev*, 84: 51–64.
- Scheller, J., Garbers, C., Rose-John, S. 2014. Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities. *Semin Immunol*, 26: 2–12.
- Scollard, D.M., Martelli, C.M., Stefani, M.M., de Fatima Maroja, M., Villahermosa, L., Pardillo, F., Tamang, K.B. 2015. Risk factors for leprosy reactions in three endemic countries. *Am J Trop Med Hyg*, 92(1): 108-114.
- Scollard, D., Smith, T., Bhoopat, L., Theetranont, C., Rangdaeng, S., Morens, D. 1994. Epidemiologic characteristics of leprosy reactions. *Int J Lepr Other Mycobact Dis*, 62: 559–567.
- Sharma, N., Koranne, R.V., Mendiratta, V., Sharma, R.C. 2004. A study of leprosy reactions in a tertiary hospital in Delhi. *J Dermatol*, 31(11): 898-903.
- Shu, J., Qiu, G., Ilyas, M. 2015. Immunohistochemistry (IHC) Image Analysis Toolbox. [online] Available at: <https://imagej.nih.gov/ij/plugins/ihc-toolbox/index.html>. [Accessed 4 April 2019].
- Siddharaju, N., Roy, S., Bundele, M., Badhe, B., Thapa, D. 2007. Fine needle aspiration cytology diagnosis of erythema nodosum leprosum. *Acta Cytol*, 51: 800–802.
- Silva, M., De Castro, M. 2012. Mycobacterial infections. In Bologna, J., Jorizzo, J., Schaffer, J., editor. *Dermatology*. 3rd ed. Elsevier, New York.
- Simpson, R.J., Hammacher, A., Smith, D.K., Matthews, J.M., Ward, L.D. 1997. Interleukin-6: Structure-function relationships. *Protein Sci*, 6(5): 929-955.
- Sousa, A.L.M., Fava, V.M., Sampaio, L.H., Martelli, C.M., Costa, M.B., Mira, M.T., Stefani, M.M. 2012. Genetic and immunological evidence implicates IL6 for leprosy type 2 reaction. *J Infect Dis*, 205: 1417-1424.
- Sousa, A.L.O., Stefani, M.M., Pereira, G.A., Costa, M.B., Rebello, P.F., Gomes, M.K., Narahashi, K., Gillis, T.P., Krahenbuhl, J.L., Martelli, C.M. 2007. *Mycobacterium leprae* DNA associated with type 1 reactions in single lesion paucibacillary leprosy treated with single dose rifampin, ofloxacin, and minocycline. *Am J Trop Med Hyg*, 77: 829-833.
- Stefani, M., Guerra, J., Sousa, A., Costa, M., Oliveira, M., Martelli, C., Scollard, D. 2009. Potential plasma markers of type 1 and type 2 leprosy reactions: A preliminary report. *BMC Infect Dis*, 9: 75.
- Suchonwanit, P., Triamchaisri, S., Wittayakornrerk, S., Rattanakaemakorn, P. 2015. Leprosy reaction in thai population: A 20-year retrospective study.



- Dermatol Res Pract*, 2015: 1-5.
- Sunandini, A., Danyasree, Suryanarayana, Subhasini, Padmasree. 2015. Case report: Type 2 lepra reaction with ulceration (erythema necroticans). *J of Evolution of Med and Dent Sci*, 4(15): 2630–2634.
- Tanaka, T., Narazaki, M., Kishimoto, T. 2014. IL-6 in inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol*, 6: 1-16.
- Teixeira, M., Silveira, V., França, E. 2010. Characteristics of leprosy reactions in paucibacillary and multibacillary individuals attended at two reference centers in Recife, Pernambuco. *Rev Soc Bras Med Trop*, 43: 287-292.
- Teles, R.M., Moraes, M.O., Geraldo, N.T., Salles, A.M., Sarno, E.N., Sampaio, E.P. 2002. Differential TNF α mRNA regulation detected in the epidermis of leprosy patients. *Arch Dermatol Res*, 294(8): 355-362.
- Thomas, M., Ponnaiya, J., Emmanuel, M., Richard, J. 2013. Type I reaction in leprosy-A histopathological analysis. *Indian J Lepr*. 85:1–4.
- Tiwari, A., Suryawanshi, P., Raikwar, A., Arif, M., Richardus, J.H. 2018. Household expenditure on leprosy outpatient services in the Indian health system: A comparative study. *PLoS Negl Trop Dis*, 12(1): 1-13.
- Unal, I. 2017. Defining an optimal cut-point value in ROC analysis: An alternative approach. *Comp Math Methods in Medicine*, 2017:1-14.
- Vieira, A.P., Trindade, M.Â.B., Pagliari, C., Avancini, J., Sakai-Valente, N.Y., da Silva Duarte, A.J., Benard, G. 2016. Development of type 2, but not type 1, leprosy reactions is associated with a severe reduction of circulating and in situ regulatory T-cells. *American J Trop Med Hyg*, 94(4): 721-727.
- Vijayakumaran, P., Manimozhi, N., Jesudasan, K. 1994. Incidence of late lepra reaction among multibacillary leprosy patients after MDT. *Int J Lepr Other Mycobact Dis*, 63: 18–22.
- Virmond, M., Grzybowski, A., Virmond, L. 2015. Leprosy: A glossary. *Clin Dermatol*, 33:8–18.
- Voorend, C., Post, E. 2013. A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction. *PLoS Negl Trop Dis*, 7: 2440.
- Walker, S., Lebas, E., Doni, S., Lockwood, D.N.J., Lambert, S., Vinetz, J.M. 2014. The mortality associated with erythema nodosum leprosum in Ethiopia: A retrospective hospital-based study. *PLoS Negl Trop Dis*, 8:e2690.
- Walker, S., Lockwood, D.N.J. 2007a. Leprosy. *Clin Dermatol*, 25: 165–172.
- Walker, S., Lockwood, D.N.J. 2008. Leprosy type 1 (reversal) reactions and their management. *Lepr Rev*, 79: 372–386.
- Walker, S.L., Waters, M.F.R., Lockwood, D.N.J. 2007b. The role of thalidomide in the management of erythema nodosum leprosum. *Lepr Rev*, 78: 197–215.
- Walschus, U., Hoene, A., Kochanowski, A., Neukirch, B., Patrzyk, M., Wilhelm, L., Schröder, K., Schlosser, M. 2011. Quantitative immunohistochemical examination of the local cellular reactions following implantation of biomaterials. *J Microsc*, 242(1): 94-99.
- Weedon, D. 2010. Leprosy. In: Weedon, D., editor. *Weedon's Skin Pathology*. 3rd ed. Elsevier: Amsterdam.
- WHO. 2008. Lepre reaction and its management [Homepage on the internet].



- New Delhi: WHO library [online]. Available at <http://www.who.int/lep/research/Reactions.pdf>. [Accessed 5 September 2018]
- WHO. 2016a. *Global Leprosy Strategy 2016–2020*. WHO Library, New Delhi.
- WHO. 2016b. *Treatment of lepra reactions*, WHO library, New Delhi.
- WHO. 2018. Global leprosy update, 2017: Reducing the disease burden due to leprosy. *WER*, 93: 445–456.
- Wilkinson, R.J., Lockwood, D.N. 2005. Antigenic trigger for type 1 reaction in leprosy. *J Infect*, 50(3): 242-243.
- Worobec, S. 2009. Treatment of leprosy/ Hansen's disease in the early 21st century. *Dermatol Ther*, 22: 518–537.
- Xie, R., Chung, J.Y., Ylaya, K., Williams, R.L., Guerrero, N., Nakatsuka, N., Badie, C., Hewitt, S.M. 2011. Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections. *J Histochem Cytochem*, 59(4): 356-365.
- Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X.F., Achong, M.K. 1998. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. *J Clin Invest*, 101(2): 311-320.
- Yang, D., Chen, J., Shi, C., Jing, Z., Song, N. 2014. Autophagy gene polymorphism is associated with susceptibility to leprosy by affecting inflammatory cytokines. *Inflammation*, 37(2): 593-598.
- Yawalkar, S. 2009. *Leprosy for medical practitioners and paramedical workers*. 8th ed. Novartis Foundation for Sustainable Development, Switzerland.